Inclusion Criteria

Criteria:

- Must be able to swallow

- Histologically confirmed solid tumor

- Advanced or metastatic disease

- Measurable or evaluable disease

- No known active CNS metastases

- ECOG performance status 0-1

- Life expectancy > 3 months

- Progressive disease during >= 1 prior standard therapy OR disease unlikely to respond
to any currently available therapies

- Patients with previously treated CNS metastases who have no evidence of new CNS
metastases AND are stable for >= 2 months are eligible

- Platelet count >= 100,000/mm^3

- Hemoglobin >= 10 g/dL (transfusions allowed)

- Absolute neutrophil count >= 1,500/mm^3

- ALT and AST =< 2.5 times upper limit of normal (ULN)

- Alkaline phosphatase =< 2.5 times ULN

- Creatinine =< 1.5 mg/dL OR creatinine clearance >= 50 mL/min

- Bilirubin normal

- PT/PTT =< 1.5 times ULN

- FEV1 >= 1.2 L

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception 2 weeks prior to and during study
treatment

- No mental deficits and/or psychiatric history that may preclude study treatment

- No active heart disease, including any of the following: myocardial infarction within
the past 3 months, symptomatic coronary artery disease or heart block, uncontrolled
congestive heart failure

- No moderate to severe compromise of pulmonary function

- No active infection

- No other life-threatening illness

- No active coagulation disorder other than occult blood

- No known positivity for glucose-6-phosphate dehydrogenase (G6PD) deficiency

- Recovered from prior treatment

- Prior gemcitabine allowed

- More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

- More than 3 weeks since prior radiotherapy or any other treatment for this cancer

- No prior 3-AP

- No concurrent radiotherapy

- No other concurrent investigational agent